Skip to content

US · ERNAW · BIOTECHNOLOGY

Ernexa Therapeutics Inc. Warrants (ERNAW) intrinsic value and stock valuation

$0.03as of 2026-11-21 · Mkt cap 298.42K

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Ernexa Therapeutics Inc. Warrants DCF and intrinsic value

InvestorsCraft values ERNAW with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ERNAW’s statements →

Ernexa Therapeutics Inc. Warrants Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Cambridge, MA 02141 ernexatx.com

How the business is doing

Fiscal 2025–2025, USD

Revenue
$0.00
20252025
Net income
-$-14.08M
20252025
Free cash flow
-$-7.05M
20252025
Total equity
$2.4M
20252025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2025–2025, USD
2025
Revenue$0.00
Operating income-$-9.32M
Net income-$-14.08M
EPSd-$-56.32M
Operating cash flow-$-7.02M
Capital expenditure-$-40K
Free cash flow-$-7.05M
Total assets$5.83M
Total debt$490K
Net debt-$-1.39M
Total equity$2.4M
Cash and short-term investments$1.88M
Income statement
2025
Revenue$0.00
Cost of revenue$260K
Gross profit-$-260K
Research and development expenses$4.16M
Selling, general and administrative expenses$4.9M
Other expenses$0.00
Operating expenses$9.06M
Cost and expenses$9.32M
Interest income$80K
Interest expense$30K
Depreciation and amortization$260K
Ebitda-$-9.06M
Operating income-$-9.32M
Total other income/expenses, net-$-4.81M
Income before tax-$-14.13M
Income tax expense-$-40K
Net income-$-14.08M
Weighted average shares outstanding$250K
Weighted average diluted shares outstanding$250K
Balance sheet
2025
Cash and short-term investments$1.88M
Net receivables$840K
Inventory$0.00
Total current assets$3.13M
Property, plant and equipment, net$550K
Goodwill and intangible assets$2.04M
Long-term investments$0.00
Total non-current assets$2.7M
Total assets$5.83M
Accounts payable$1.12M
Short-term debt$210K
Deferred revenue$0.00
Total current liabilities$3.11M
Long-term debt$280K
Deferred revenue, non-current$0.00
Total non-current liabilities$320K
Capital lease obligations$280K
Total liabilities$3.43M
Common stock$40K
Retained earnings-$-245.64M
Accumulated other comprehensive income (loss)$0.00
Total equity$2.4M
Total investments$0.00
Total debt$490K
Net debt-$-1.39M
Cash flow statement
2025
Net income-$-14.08M
Depreciation and amortization$260K
Stock-based compensation$0.00
Change in working capital-$-50K
Accounts receivable-$-410K
Inventory$0.00
Accounts payable$60K
Net cash provided by operating activities-$-7.02M
Investments in property, plant and equipment-$-40K
Acquisitions, net$0.00
Net cash used for investing activities-$-40K
Common stock issued$4.96M
Common stock repurchased$0.00
Dividends paid$0.00
Net cash used for financing activities$7.21M
Net change in cash$150K
Cash at end of period$1.88M
Operating cash flow-$-7.02M
Capital expenditure-$-40K
Free cash flow-$-7.05M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Ernexa Therapeutics Inc. Warrants

        Operating in the preclinical phase, Ernexa Therapeutics Inc. is dedicated to advancing therapies based on induced mesenchymal stem cells (iMSC) to combat both solid tumors and autoimmune conditions. Its primary therapeutic, ERNA-101, is an allogeneic iMSC specifically formulated to secrete pro-inflammatory cytokines like IL-7 and IL-15 for the treatment of ovarian cancer. Complementing this, ERNA-102 is another iMSC designed to deliver the anti-inflammatory cytokine IL-10, targeting rheumatoid arthritis. Ernexa Therapeutics has secured a licensing agreement with Factor Bioscience Limited. The company, founded in 2018 and headquartered in Cambridge, Massachusetts, was formerly named Eterna Therapeutics Inc., before officially changing to Ernexa Therapeutics in March 2025.

        CEO
        Sanjeev Luther
        Employees
        5
        Beta
        2.51

        Explore

        Frequently asked questions

        What is the intrinsic value of Ernexa Therapeutics Inc. Warrants (ERNAW)?

        InvestorsCraft does not currently publish an intrinsic value for ERNAW. How the IC value is calculated.

        Is ERNAW undervalued?

        InvestorsCraft does not publish an undervaluation signal for ERNAW at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.